Association between pharmacy medication refill-based adherence rates and cd4 count and viral-load responses: A retrospective analysis in treatment-experienced adults with HIV

Clinical Therapeutics

Volumn 29, Issue 4, 2007, Pages 711-716

  Townsend, Mary L ^a,b   Jackson, George L ^a,c   Smith, Rose ^a   Wilson, Kenneth H ^a,c  

^a Health Services Research   (United States)

^b CAMPBELL UNIVERSITY   (United States)

^c DUKE UNIVERSITY HOSPITAL   (United States)

Author keywords

antiretroviral therapy; CD4 count; drug adherence; HIV infection; viral load

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; CD4 LYMPHOCYTE COUNT; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE MARKER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATA COLLECTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PATIENT COMPLIANCE; PHARMACY SERVICE, HOSPITAL; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 34347337513     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.04.006     Document Type: Article

References (21)

1. Gross R., Bilker W.B., Friedman H.M., and Strom B.L. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 16 (2001) 2109-2117
2. Low-Beer S., Yip B., O'Shaughnessy M.V., et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 23 (2000) 360-361
3. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 17 (2003) 169-177
4. [published correction appears in Ann Intern Med. 2002;136:253]. Paterson D.L., Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 133 (2000) 21-30
5. Maggiolo F., Ravasio L., Ripamonti D., et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 40 (2005) 158-163
6. Bangsberg D.R., Charlebois E.D., Grant R.M., et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17 (2003) 1925-1932
7. Bangsberg D.R., Porco T.C., Kagay C., et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis. 190 (2004) 162-165
8. Bangsberg D.R., Hecht F.M., Charlebois E.D., et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14 (2000) 357-366
9. [published correction appears in Clin Infect Dis. 2006;43: 672]. Nettles R.E., Kieffer T.L., Parsons T., et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 42 (2006) 1189-1196
10. Barrett J.S., Joshi A.S., Chai M., et al. Population pharmacokinetic metaanalysis with efavirenz. Int J Clin Pharmacol Ther. 40 (2002) 507-519
11. Goujard C., Legrand M., Panhard X., et al., COPHAR1-ANRS 102 Study Group. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy. Clin Pharmacokinet. 44 (2005) 1267-1278
12. Seattle, Wash. Abstract 428-W. Wegner S., Vahey M., Dolan M., et al. Racial differences in clinical efficacy of efavirenz-based antiretroviral therapy. Presented at: 9th Conference on Retroviruses and Opportunistic Infections (February 2002)
13. Glasgow UK. Abstract P61. Lupo L.J., Maa J.-F., Dezil C.M., et al. Efficacy ofefavirenz in different racial groups. Presented at: 6th Inter national Congress on Drug Therapy in HIV Infections (November 2002)
14. Bangsberg D.R., Hecht F.M., Clague H., et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 26 (2001) 435-442
15. Miller L.G., Liu H., Hays R.D., et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy?. J Gen Intern Med. 17 (2002) 1-11
16. [published correction appears in Ann Intern Med. 2002;136: 175]. Liu H., Golin C.E., Miller L.G., et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 134 (2001) 968-977
17. Grossberg R., Zhang Y., and Gross R. A time-to-prescription-refill measure of antiretroviral adherence predict ed changes in viral load in HIV. J Clin Epidemiol. 57 (2004) 1107-1110
18. Kitahata M.M., Reed S.D., Dillingham P.W., et al. Pharmacy-based assessment of adherence to HAART pre dicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 15 (2004) 803-810
19. Steiner J.F., Koepsell T.D., Fihn S.D., and Inui T.S. A general method ofcompliance assessment using centralized pharmacy records. Description and validation. Med Care. 26 (1988) 814-823
20. Christensen D.B., Williams B., Goldberg H.I., et al. Assessing compliance to anti hypertensive medications using computer-based pharmacy records. Med Care 35 (1997) 1164-1170
21. Choo P.W., Rand C.S., Inui T.S., et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to anti hypertensive therapy. Med Care 37 (1999) 846-857